Multicentric Castleman Disease of the Supraglottis: A Surgeons’ Dilemma

Document Type : Case Report


1 Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, University Kebangsaan Malaysia Medical Centre, 56000 Kuala Lumpur, Malaysia.

2 Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Center, 56000 Kuala Lumpur, Malaysia


An abnormal mass in the head and neck involving the supraglottic and cervical region offers a wide range of differential diagnoses. The pathology is either benign or malignant in nature. Castleman disease (CD) is an uncommon lymphoproliferative disorder characterised by hypervascular lymphoid hyperplasia and is classified into unicentric or multicentric disease. Histopathologically it is divided into hyaline vascular (HV), plasma cell (PC), and mixed cellularity variants. The multicentric disease is linked with PC and has the propensity to progress to lymphoma or Kaposi Sarcoma.
Case Report:
We report a case of a 45-year-old gentleman who presented with a painless anterior neck swelling and left supraglottic mass for six months. Computed tomography (CT) contrast imaging demonstrated a homogenous enhancing lesion at the left supraglottic and the midline of the anterior neck with erosive changes of the thyroid cartilage. A surgical resection of the anterior neck mass was performed. The diagnosis of Castleman disease plasma cell variant was made by histopathologic evaluation. The patient remained well post-resection.
Supraglottic multicentric Castleman disease is the least expected diagnosis in this case. Unicentric disease is treated with surgery. However, limited studies are available in determining the effectiveness of surgery in multicentric diseases. The plasma cell variant requires a multidisciplinary and multimodal approach due to an inclination towards malignancy. Research is needed to determine the role of surgery in multicentric disease and to develop optimum guidelines for managing cases. To date, there is unsubstantial literature describing supraglottic multicentric disease.


  1. Reny D,. Jhala D, Mirza N. Unicentric Castleman Disease and lymphoepithelial cyst of the parotid: A case report and review of the literature. Oral Science International. 2020;17(2): 106-110.
  2. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol. 2005 May;6(3):255-66.
  3. Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316-24.
  4. Castleman B, Iverson L, Menendez Vp. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 Jul-Aug;9(4):822-30..
  5. Boochoon KS, Barbieri AN, Mohyuddin NG. An Abnormal Neck Mass in a Pediatric Patient. JAMA Otolaryngol Head Neck Surg. 2020 Apr 1;146(4):375-376.
  6. Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, Raphael M. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002 Feb;69(2):119-26.
  7. Yi AY, deTar M, Becker TS, Rice DH. Giant lymph node hyperplasia of the head and neck (Castleman's disease): a report of five cases. Otolaryngol Head Neck Surg. 1995 Oct;113(4):462-6.
  8. Song JJ, Jung MH, Woo JS, Chae SW, Hwang SJ, Lee HM. Castleman's disease of the head and neck. Eur Arch Otorhinolaryngol. 2006 Feb;263(2):160-3.
  9. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012 Apr;255(4):677-84.
  10. Schulte KM, Talat N. Castleman's disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol. 2010 Sep;7(9):533-43.
  11. Liu AY, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr;3(4):e163-75.
  12. Wang T, Chen X, Chen W, Shi L, Liu J. A retrospective study of 44 patients with head and neck Castleman's disease. Eur Arch Otorhinolaryngol. 2022 May;279(5):2625-2630.
  13. Rabinowitz MR, Levi J, Conard K, Shah UK. Castleman disease in the pediatric neck: a literature review. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1028-36.
  14. Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May;56(5):1252-60.
  15. Alzahrani MF, Radwi M, Leitch HA. Practical Management of Castleman's Disease. Acta Haematol. 2016;136(1):16-22.
  16. Jiang L, Zhao LY, Liu Y, Zhao YF. Castleman's disease of the neck: report of 4 cases with unusual presentations. J Oral Maxillofac Surg. 2011 Apr; 69(4): 1094-9.
  17. Bowne WB et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999 Feb 1;85(3):706-17.
  18. Bower M, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007 Dec 18;147(12):836-9.
  19. Kurzrock R et al. A phase I, open-label study
    of siltuximab, an anti-IL-6  monoclonal  antibody, in


patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 1;19(13):3659-70.

  1. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol. 2008 Jun;83(6):498-503.
  2. Oksenhendler E, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996 Jan;10(1):61-7.